CO5031247A1 - Compuestos triciclicos sustituidos - Google Patents

Compuestos triciclicos sustituidos

Info

Publication number
CO5031247A1
CO5031247A1 CO99022884A CO99022884A CO5031247A1 CO 5031247 A1 CO5031247 A1 CO 5031247A1 CO 99022884 A CO99022884 A CO 99022884A CO 99022884 A CO99022884 A CO 99022884A CO 5031247 A1 CO5031247 A1 CO 5031247A1
Authority
CO
Colombia
Prior art keywords
carbamoylcarbazol
methyl
oxyacetic acid
sodium salt
oxyacetic
Prior art date
Application number
CO99022884A
Other languages
English (en)
Spanish (es)
Inventor
Benjamin Alan Anderson
James Bach Nicholas
Jolie Anne Bastian
Nancy Kay Harn
Richard Waltz Harper
Gary Alan Hite
Michael Dean Hinnick
Lin Ho-Shen
Richard James Loncharich
Edward David Mihelich
Junior John Michael Morin
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO5031247A1 publication Critical patent/CO5031247A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/82Carbazoles; Hydrogenated carbazoles
    • C07D209/88Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/58[b]- or [c]-condensed
    • C07D209/70[b]- or [c]-condensed containing carbocyclic rings other than six-membered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CO99022884A 1998-04-17 1999-04-16 Compuestos triciclicos sustituidos CO5031247A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6232898A 1998-04-17 1998-04-17

Publications (1)

Publication Number Publication Date
CO5031247A1 true CO5031247A1 (es) 2001-04-27

Family

ID=22041763

Family Applications (2)

Application Number Title Priority Date Filing Date
CO99022884A CO5031247A1 (es) 1998-04-17 1999-04-16 Compuestos triciclicos sustituidos
CO99022897A CO5011054A1 (es) 1998-04-17 1999-04-16 Compuestos triciclicos sustituidos

Family Applications After (1)

Application Number Title Priority Date Filing Date
CO99022897A CO5011054A1 (es) 1998-04-17 1999-04-16 Compuestos triciclicos sustituidos

Country Status (30)

Country Link
EP (2) EP0950657B1 (enExample)
JP (2) JP4435330B2 (enExample)
KR (2) KR100586761B1 (enExample)
CN (1) CN1149193C (enExample)
AR (2) AR018593A1 (enExample)
AT (2) ATE271037T1 (enExample)
AU (2) AU753547B2 (enExample)
BR (2) BR9902365A (enExample)
CA (2) CA2269246C (enExample)
CO (2) CO5031247A1 (enExample)
CZ (2) CZ136999A3 (enExample)
DE (2) DE69917833T2 (enExample)
DK (1) DK0950657T3 (enExample)
DZ (1) DZ2769A1 (enExample)
EA (2) EA002347B1 (enExample)
ES (2) ES2222663T3 (enExample)
HU (2) HUP9901220A3 (enExample)
ID (2) ID23287A (enExample)
IL (2) IL129483A0 (enExample)
NO (2) NO314400B1 (enExample)
NZ (3) NZ507564A (enExample)
PE (2) PE20000476A1 (enExample)
PL (2) PL332566A1 (enExample)
PT (1) PT950657E (enExample)
SG (2) SG81976A1 (enExample)
SI (1) SI0950657T1 (enExample)
TR (2) TR199900843A2 (enExample)
TW (1) TWI238160B (enExample)
YU (2) YU19199A (enExample)
ZA (2) ZA992771B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2301586A1 (en) * 1997-08-28 1999-03-04 William Louis Macias Method for treatment of non-rheumatoid arthritis
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.
AU1940800A (en) * 1998-12-21 2000-07-12 Eli Lilly And Company Combination therapy for the treatment of sepsis
CA2379208A1 (en) * 1999-07-19 2001-01-25 Eli Lilly & Company Spla2 inhibitors
US6706752B1 (en) 1999-07-19 2004-03-16 Eli Lilly And Company sPLA2 inhibitors
AU2001267826A1 (en) * 2000-06-29 2002-01-08 Shionogi And Co., Ltd. Remedies for alzheimer's disease
WO2002000256A1 (fr) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedes contre la cirrhose
WO2002000255A1 (en) * 2000-06-29 2002-01-03 Shionogi & Co., Ltd. Remedies for cancer
EP1303262A2 (en) * 2000-07-14 2003-04-23 Eli Lilly And Company Use of a spla2 inhibitor for the treatment of sepsis
US6872743B2 (en) 2000-12-18 2005-03-29 Eli Lilly And Company sPLA2 inhibitors
US6933313B2 (en) 2001-03-28 2005-08-23 Eli Lilly And Company Substituted carbazoles as inhibitors of sPLA2
AUPS282602A0 (en) 2002-06-07 2002-06-27 Garvan Institute Of Medical Research Method of inhibiting cell proliferation
DE10249055A1 (de) 2002-10-22 2004-05-06 Bayer Cropscience Ag 2-Phenyl-2-substituierte-1,3-diketone
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
EP1988098A1 (en) * 2007-04-27 2008-11-05 AEterna Zentaris GmbH Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors
CA2719721C (en) 2008-03-26 2012-12-18 Daiichi Sankyo Company, Limited Tetrahydroisoquinoline derivative
AU2009233711B2 (en) 2008-04-09 2015-02-12 Infinity Pharmaceuticals, Inc Inhibitors of fatty acid amide hydrolase
US8580795B2 (en) 2009-01-22 2013-11-12 Orchid Chemicals & Pharmaceuticals Limited Heterocyclic compounds as phosphodiesterase inhibitors
WO2010118159A1 (en) 2009-04-07 2010-10-14 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
EP2416660B1 (en) 2009-04-07 2014-07-02 Infinity Pharmaceuticals, Inc. Inhibitors of fatty acid amide hydrolase
EP2531511A1 (en) 2010-02-03 2012-12-12 Infinity Pharmaceuticals, Inc. Fatty acid amide hydrolase inhibitors
AR088377A1 (es) 2011-10-20 2014-05-28 Siena Biotech Spa Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta
CN102816107B (zh) * 2012-08-20 2015-06-03 东南大学 咔唑衍生物及其制备方法与用途
CN104797559A (zh) * 2012-11-30 2015-07-22 通用电气健康护理有限公司 卤化锌介导的环化过程得到三环吲哚
CN111362863A (zh) 2012-11-30 2020-07-03 通用电气健康护理有限公司 三环吲哚衍生物的结晶方法
EP3248230B1 (de) * 2015-01-20 2020-05-06 cynora GmbH Verwendung organischer moleküle in optoelektronischen bauelementen
CN108707104A (zh) * 2018-08-07 2018-10-26 北京恒信卓元科技有限公司 2-氯-1h-咔唑-1,4(9h)-二酮的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3579534A (en) * 1969-05-09 1971-05-18 American Cyanamid Co Tetrahydrocarbazolecarboxylates
US3979391A (en) * 1972-11-22 1976-09-07 Sterling Drug Inc. 1,2,3,4-Tetrahydrocarbazoles
US3939177A (en) * 1972-11-22 1976-02-17 Sterling Drug Inc. 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles
US5420289A (en) * 1989-10-27 1995-05-30 American Home Products Corporation Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase
PT95692A (pt) * 1989-10-27 1991-09-13 American Home Prod Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase
WO1993001169A2 (en) * 1991-07-05 1993-01-21 Merck Sharp & Dohme Limited Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
IL109309A (en) * 1993-04-16 2000-06-29 Lilly Co Eli 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them
IL109311A0 (en) * 1993-04-16 1994-07-31 Lilly Co Eli 1H-indole-3-acetamide sPla2 inhibitors
CA2179678A1 (en) * 1995-06-23 1996-12-24 Michael Edward Flaugh 6-substituted-1,2,3,4-tetrahydro-9h-carbazoles and 7-substituted-10h-cyclohepta¬7,6-b| indoles
US6160175A (en) * 1995-12-13 2000-12-12 Eli Lilly And Company Naphthyl acetamides as sPLA2 inhibitors
KR20000049210A (ko) * 1996-10-30 2000-07-25 피터 지. 스트링거 치환된 트리시클릭류
CA2304482A1 (en) * 1997-09-26 1999-04-08 Eli Lilly And Company Method for the treatment of cystic fibrosis
CA2310250A1 (en) * 1997-11-14 1999-05-27 August Masaru Watanabe Treatment for alzheimer's disease
DZ2769A1 (fr) * 1998-04-17 2003-12-01 Lilly Co Eli Composés tricycliques substitués.

Also Published As

Publication number Publication date
CA2269246C (en) 2009-08-25
AU753436B2 (en) 2002-10-17
BR9902365A (pt) 2001-04-24
PL332566A1 (en) 1999-10-25
IL129485A0 (en) 2000-02-29
EA199900301A3 (ru) 2000-04-24
YU18999A (sh) 2002-08-12
EA199900303A2 (ru) 1999-10-28
EP0952149A2 (en) 1999-10-27
ATE268756T1 (de) 2004-06-15
NO991822L (no) 1999-10-18
PT950657E (pt) 2004-11-30
AU753547B2 (en) 2002-10-24
CA2269246A1 (en) 1999-10-17
EP0950657B1 (en) 2004-07-14
HUP9901221A3 (en) 2001-11-28
DE69917833T2 (de) 2005-07-14
EA002816B1 (ru) 2002-10-31
CN1253948A (zh) 2000-05-24
NO991822D0 (no) 1999-04-16
NZ507564A (en) 2002-10-25
HUP9901220A3 (en) 2001-11-28
PE20000432A1 (es) 2000-05-23
NO991821D0 (no) 1999-04-16
AU2381799A (en) 1999-10-28
SI0950657T1 (en) 2005-02-28
PL332565A1 (en) 1999-10-25
JP2000026416A (ja) 2000-01-25
HU9901221A (hu) 2000-04-28
NZ335253A (en) 2000-11-24
CN1149193C (zh) 2004-05-12
DE69917833D1 (de) 2004-07-15
ES2222663T3 (es) 2005-02-01
ATE271037T1 (de) 2004-07-15
JP4435330B2 (ja) 2010-03-17
ES2226286T3 (es) 2005-03-16
EP0952149A3 (en) 2001-08-16
DE69918590T2 (de) 2005-07-21
NO312240B1 (no) 2002-04-15
TR199900853A3 (tr) 1999-11-22
AU2381999A (en) 1999-10-28
IL129483A0 (en) 2000-02-29
EP0952149B1 (en) 2004-06-09
HU9901220A (hu) 2000-04-28
AR018186A1 (es) 2001-10-31
ZA992771B (en) 2002-04-18
EP0950657A2 (en) 1999-10-20
ID23287A (id) 2000-04-05
NZ335251A (en) 2000-11-24
YU19199A (sh) 2002-08-12
DK0950657T3 (da) 2004-11-22
JPH11322713A (ja) 1999-11-24
HU9901220D0 (en) 1999-06-28
ZA992772B (en) 2002-07-16
DE69918590D1 (de) 2004-08-19
TR199900853A2 (xx) 1999-11-22
BR9901279A (pt) 2000-05-02
AR018593A1 (es) 2001-11-28
NO314400B1 (no) 2003-03-17
CZ137099A3 (cs) 1999-11-17
CO5011054A1 (es) 2001-02-28
EA199900301A2 (ru) 1999-10-28
KR19990083232A (ko) 1999-11-25
HU9901221D0 (en) 1999-06-28
TR199900843A2 (xx) 2000-02-21
SG81976A1 (en) 2001-07-24
TWI238160B (en) 2005-08-21
CZ136999A3 (cs) 1999-11-17
PE20000476A1 (es) 2000-06-02
EP0950657A3 (en) 2001-08-16
SG81977A1 (en) 2001-07-24
CA2269262A1 (en) 1999-10-17
DZ2769A1 (fr) 2003-12-01
KR100586761B1 (ko) 2006-06-08
KR19990083233A (ko) 1999-11-25
NO991821L (no) 1999-10-18
EA002347B1 (ru) 2002-04-25
EA199900303A3 (ru) 2000-04-24
ID23761A (id) 2000-05-11

Similar Documents

Publication Publication Date Title
GB2392154B (en) Protein Kinase Inhibitors
GB2398781B (en) Kinase inhibitors
SG128491A1 (en) Heterocyclic sulfonamide inhibitors of beta amyloid production
TR200100432T2 (tr) Hepatit C inhibitörü tri-peptidler
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
ES2266459T3 (es) Uso de compuestos de azetidinona sustituidos para el tratamiento de sitosterolemia.
ECSP045229A (es) Piridinonas sustituidas como moduladores de la p38 map quinasa
AR042273A1 (es) Derivados de pirazol, procedimiento para prepararlos y las composiciones farmaceuticas que los contienen
AR025386A1 (es) Moduladores de los receptores activados del proliferador de peroxisomas
ES2170252T3 (es) Tetrahidroimidazopiridoindoldionas como inhibidores de cgmp especifico pde.
AR006720A1 (es) Un compuesto derivado de azahexano heterociclico, su uso para la preparacion de una composicion farmaceutica, procedimiento para prepararlo y una composicion farmaceutica que lo comprende
NZ335253A (en) certain [9-(cycloalkylmethyl or phenylmethyl)-5-carbamoyl-carbazol-4-yl]oxyacetic acid derivatives
ES2136037B1 (es) Inhibidores de sulfamida-metaloproteasa
NO883487L (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske forbindelser.
CO4480737A1 (es) Compuestos parasiticidas
ES2193252T3 (es) Quinolonas y su uso terapeutico.
ES2123652T3 (es) 7-(2-aminoetil)-benzotiazolonas.
DK0759919T3 (da) Azolidindioner som antihyperglykæmiske midler
CO4900054A1 (es) Pirroles sustituidos
TR200001452T2 (tr) Bifenilamidin türevleri.
EP1331224A4 (en) THIAZOLE AND OXAZOLE DERIVATIVES
DK0456209T3 (da) Bis(alkylsubstituerede-4-hydroxyphenylthio)alkananaloger som inhibitorer af kataraktdannelse
DE69933885D1 (de) Triphenylbutenderivate zur behandlung von neurologischen störungen
SV1998000151A (es) Compuestos de triazina
MXPA02003952A (es) Derivados de imidazol como inhibidores de la fosfodieterasa vii.